-
Rain Oncology's Phase 3 Data Casts Doubt On Other Trials: Analyst Reevaluate Their Views
Tuesday, May 23, 2023 - 11:19am | 676Read More...Shares of Rain Oncology Inc (NASDAQ: RAIN) recovered in early trading on Tuesday, after having plummeted on disappointing cancer study data. Here are some key analyst takeaways from the company’s decision to halt studies for its lead candidate as a treatment for dedifferentiated (DD)...
-
3 Reasons Goldman Sachs Is Bullish On Kodiak Sciences
Tuesday, March 3, 2020 - 1:08pm | 304Read More...Kodiak Sciences Inc’s (NASDAQ: KOD) main drug candidate, KSI-301, highlights the company’s focus on innovation in a dynamic treatment landscape, according to Goldman Sachs. The Kodiak Sciences Analyst Graig Suvannavejh initiated coverage of Kodiak Sciences with a Buy rating and a price...
-
Positive Data From Orchard Therapeutics Turns Goldman Sachs Bullish
Monday, December 17, 2018 - 1:16pm | 454Read More...Orchard Therapeutics PLC – ADR (NASDAQ: ORTX), a rare disease gene therapy company, recently went public, offering 14.29 million shares at $14 each. The shares were listed on the Nasdaq Oct. 31 and ended the session flat. Goldman Sachs, which initiated the stock with a Neutral Nov. 26, has...
-
Jefferies & Company Likes Endo Pharmaceuticals (ENDP) Acquisition Plans
Thursday, May 6, 2010 - 9:17am | 168Read More...Jefferies & Company analysts Corey Davis, Graig Suvannavejh and Oren G. Livnat maintained their Buy rating for shares of Endo Pharmaceuticals (NASDAQ: ENDP), with a price target of $26 per share. The analysts wrote that after announcing plans to acquire HealthTronics Inc. (NASDAQ: HTRN) for $...
